Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nonmyeloablative Conditioning for Mismatched HSCT in Severe Sickle Cell Disease
NCT02678143Phase 1Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Apr 2016
- Primary completion
- Apr 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of allogeneic hematopoietic stem cells in sickle cell disease (SCD), sponsored by Washington University School of Medicine. Primary endpoint: Safety and tolerability of treatment regimen as measured by grade 3, 4, and 5 toxicities at Day 180. Started Apr 2016; status: terminated.
02
Drugs
allogeneic hematopoietic stem cells
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT02678143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02678143.